Court Rejects Pfizer's Bid To Block Metsera Board From Considering Novo Nordisk's $10 Bln Offer

The Delaware Court of Chancery rejected Pfizer's request for a temporary restraining order to prevent Metsera from considering a rival acquisition offer from Novo Nordisk. Metsera welcomed the decision, affirming its commitment to shareholder interests, while Pfizer maintains Metsera breached contractual obligations and vows to continue litigation, alleging Novo Nordisk's proposal is an "illusory" attempt to bypass antitrust scrutiny. Novo Nordisk's revised offer, deemed superior by Metsera, totals up to $86.20 per share, including a contingent value right, valuing the company at approximately $10 billion, significantly higher than Pfizer's previous bid.

Analysis

The Delaware Court of Chancery's rejection of Pfizer's request for a temporary restraining order against Metsera marks a significant development, allowing Metsera's Board to formally consider Novo Nordisk's rival acquisition offer. Metsera welcomed this decision, reaffirming its commitment to shareholder interests, while dismissing Pfizer's ongoing litigation as unfounded. This ruling clears an immediate hurdle for the bidding process to proceed.

Novo Nordisk's revised proposal, deemed superior by Metsera, offers up to $86.20 per share, comprising $62.20 in cash and a contingent value right of up to $24. This values Metsera at approximately $10 billion, representing a substantial 159% premium to its closing price on September 19, 2025. This significantly surpasses Pfizer's previous bid of $60 cash and up to $10 CVR, totaling $70 per share.

Despite the court's decision, Pfizer maintains its position, asserting Metsera breached contractual obligations and failed in its fiduciary duties. Pfizer intends to pursue claims through ongoing litigation and a parallel antitrust case, labeling Novo Nordisk's offer as an "illusory" attempt to bypass regulatory scrutiny. This indicates continued legal uncertainty and potential delays for the acquisition process.

Key Decisions for Investors

• Metsera shareholders should evaluate the enhanced value proposition of Novo Nordisk's $86.20 per share offer, considering the significant premium and the immediate cash component.
• Investors should closely monitor the ongoing legal challenges from Pfizer, as continued litigation and antitrust scrutiny could introduce deal uncertainty and impact the transaction timeline.
• Consider the strategic implications for Pfizer and Novo Nordisk; Pfizer's aggressive stance signals its commitment to the asset, while Novo Nordisk's higher bid reflects its strategic imperative in this competitive M&A landscape.